Donald Trump’s tariff tussle: Duties on Indian pharma would be ‘counterproductive’; America may take at least 3 years to match India’s scale, says Pharmexcil

Despite increased tariffs on Indian imports, the US has temporarily exempted the pharmaceutical sector, recognizing India’s critical role in supplying affordable medicines. Pharmexcil emphasizes that tariffs on Indian pharma would harm American consumers, as Indian companies produce low-cost generics. India supplies over 40% of US generic medicines, maintaining high quality standards with numerous FDA-approved facilities.

Read More

US jobless data: More Americans seek unemployment support; modest rise amid growing tariff tensions

In US, jobless claims saw a slight increase last week. The rise hints at employers retaining staff despite trade uncertainties. Initial claims reached 226,000, surpassing expectations. This data offers a glimpse into the job market after a weak July report. The four-week moving average provides a stable trend view. Continuing claims also jumped, reaching the…

Read More

RBI survey: Merchandise imports to grow twice more than exports in FY26; check details

Reserve Bank of India forecasts a rise in India’s merchandise imports. Imports are expected to grow faster than exports in the coming financial years. This trade gap may impact India’s external balance. GDP is projected to grow steadily. Private consumption and capital formation are also expected to increase. Inflation is estimated to remain moderate initially,…

Read More

Donald Trump’s 25% additional tariff on India: What are ‘secondary tariffs’ and how do they differ from ‘secondary sanctions’? Explained

Donald Trump has announced a 25% ‘secondary tariff’ on Indian goods, effective August 27, to penalize India’s oil purchases from Russia. This aims to pressure India to sever ties with Russia, similar to secondary sanctions. The US tracks oil tanker movements via satellite to monitor countries buying Russian oil.

Read More